5-HT7 receptor activation attenuates thermal hyperalgesia in streptozocin-induced diabetic mice

Basit Öğe Kaydı
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridGunduz, Ozgur/0000-0002-2470-3021
dc.authoridOltulu, Cagatay/0000-0002-6051-3479
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidGÜNDÜZ, Özgür/AAH-8717-2019
dc.authorwosidShaghaghi, Mohammadreza/L-9134-2016
dc.authorwosidGunduz, Ozgur/A-2351-2016
dc.authorwosidOltulu, Cagatay/V-1823-2018
dc.contributor.authorUlugol, Ahmet
dc.contributor.authorOltulu, Cagatay
dc.contributor.authorGunduz, Ozgur
dc.contributor.authorCitak, Cihad
dc.contributor.authorCarrara, Roberto
dc.contributor.authorShaqaqi, Mohammad Reza
dc.contributor.authorMansilla Sanchez, Alicia
dc.date.accessioned2024-06-12T10:59:26Z
dc.date.available2024-06-12T10:59:26Z
dc.date.issued2012
dc.departmentTrakya Üniversitesien_US
dc.description14th World Congress on Pain -- AUG 27-31, 2012 -- Milan, ITALYen_US
dc.description.abstractThe role of 5-HT7 receptors in the nociceptive processing received most attention during the last few years. The involvement of 5-HT7 receptors in nerve injury-induced neuropathic pain states have been reported only recently; however, there are no reports on its contribution in diabetic neuropathic pain. We therefore planned to investigate the effect of 5-HT7 receptor activation on the changes of nociceptive threshold in diabetic mice. Diabetes was induced by a single intraperitoneal injection of streptozocin (150 mg/kg, i.p.). The nociceptive responses in normal and diabetic animals were tested in the hot-plate and tail-flick assays. Both hot-plate and tail-flick latencies significantly shortened at 1-3/4 weeks (thermal hyperalgesia) and prolonged at 6-7 weeks (thermal hypoalgesia) after streptozocin administration. At the dose of 10 mg/kg, systemic injections of AS-19, a selective 5-HT7 receptor agonist, reduced thermal hyperalgesia at early stage of diabetes, but did not influence thermal hypoalgesia at late stage. Co-administration of SB-258719, a selective 5-HT7 receptor antagonist, at a dose that had no effect on its own (10 mg/kg), reversed the anti-hyperalgesic effect of AS-19. Our results indicate that systemic administration of 5-HT7 receptor agonists may have clinical utility in treating diabetic neuropathic pain. (C) 2012 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.pbb.2012.05.006
dc.identifier.endpage348en_US
dc.identifier.issn0091-3057
dc.identifier.issue2en_US
dc.identifier.pmid22609798en_US
dc.identifier.scopus2-s2.0-84861815482en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage344en_US
dc.identifier.urihttps://doi.org/10.1016/j.pbb.2012.05.006
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20451
dc.identifier.volume102en_US
dc.identifier.wosWOS:000306776000022en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofPharmacology Biochemistry And Behavioren_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetesen_US
dc.subjectThermal Hyperalgesiaen_US
dc.subjectThermal Hypoalgesiaen_US
dc.subjectSerotoninen_US
dc.subject5-HT7 Receptorsen_US
dc.subjectDescending Serotonergic Pathwaysen_US
dc.subjectSpinal 5-Ht7en_US
dc.subjectTactile Allodyniaen_US
dc.subjectNeuropathic Painen_US
dc.subjectModelen_US
dc.subjectAntinociceptionen_US
dc.subjectPathogenesisen_US
dc.subjectRatsen_US
dc.title5-HT7 receptor activation attenuates thermal hyperalgesia in streptozocin-induced diabetic miceen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu